莱茵生物
(002166)
| 流通市值：58.33亿 | | | 总市值：58.74亿 |
| 流通股本：7.36亿 | | | 总股本：7.42亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 836,964,658.02 | 444,292,336.62 | 1,771,759,914.59 | 1,169,965,060.76 |
| 营业收入 | 836,964,658.02 | 444,292,336.62 | 1,771,759,914.59 | 1,169,965,060.76 |
| 二、营业总成本 | 784,217,763.94 | 402,259,540.14 | 1,555,734,975.45 | 1,055,454,984.4 |
| 营业成本 | 639,724,970.48 | 346,461,298.63 | 1,252,185,948.37 | 840,516,661.85 |
| 税金及附加 | 5,212,071.79 | 2,631,579.92 | 10,623,186.32 | 3,171,474.18 |
| 销售费用 | 32,472,162.32 | 13,792,872.62 | 63,518,766.06 | 42,410,232.17 |
| 管理费用 | 62,143,099.21 | 19,807,613.51 | 140,967,380.72 | 97,158,131.75 |
| 研发费用 | 26,217,118.08 | 11,524,403.03 | 57,502,496.09 | 47,363,853.57 |
| 财务费用 | 18,448,342.06 | 8,041,772.43 | 30,937,197.89 | 24,834,630.88 |
| 其中:利息费用 | 20,519,180.34 | 9,945,977.17 | 42,238,324.33 | 30,930,108.73 |
| 其中:利息收入 | 1,237,839.71 | 587,224.95 | 4,228,499.93 | 2,920,421.73 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -207,129.89 | -5,093,335.39 | 2,025,062.21 | -6,609,671.77 |
| 加:投资收益 | 74,624.01 | -430.56 | 7,178,829 | 7,179,333.59 |
| 资产处置收益 | -109,497.53 | -497,755.13 | -523,831.47 | 6,660.58 |
| 资产减值损失(新) | -422,147.6 | -148,445.63 | -21,463,296.06 | 672,135.1 |
| 信用减值损失(新) | 1,590,905.19 | 1,523,374.58 | -16,076,345.8 | 2,425,743.85 |
| 其他收益 | 9,615,476.57 | 1,582,440.51 | 26,262,839.44 | 15,938,390.85 |
| 四、营业利润 | 63,289,124.83 | 39,398,644.86 | 213,428,196.46 | 134,122,668.56 |
| 加:营业外收入 | 22,342.68 | 459.73 | 700,624.86 | -8,195.79 |
| 减:营业外支出 | 945,230.92 | 200.98 | 6,291,647.27 | 6,371,083.91 |
| 五、利润总额 | 62,366,236.59 | 39,398,903.61 | 207,837,174.05 | 127,743,388.86 |
| 减:所得税费用 | 18,693,815.48 | 6,728,348.57 | 40,663,181.48 | 21,727,600.37 |
| 六、净利润 | 43,672,421.11 | 32,670,555.04 | 167,173,992.57 | 106,015,788.49 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 43,672,421.11 | 32,670,555.04 | 167,173,992.57 | 106,015,788.49 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 38,109,978.8 | 30,794,889.8 | 163,008,773.57 | 101,621,708.59 |
| 少数股东损益 | 5,562,442.31 | 1,875,665.24 | 4,165,219 | 4,394,079.9 |
| 扣除非经常损益后的净利润 | 33,693,373.75 | 36,135,337.34 | 151,358,130.25 | 104,525,118.79 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.05 | 0.04 | 0.22 | 0.14 |
| (二)稀释每股收益 | 0.05 | 0.04 | 0.22 | 0.14 |
| 八、其他综合收益 | 2,319,069.71 | 111,245.14 | 10,901,157.76 | -2,080,182.64 |
| 归属于母公司股东的其他综合收益 | 2,319,069.71 | 111,245.14 | 10,901,157.76 | -2,080,182.64 |
| 九、综合收益总额 | 45,991,490.82 | 32,781,800.18 | 178,075,150.33 | 103,935,605.85 |
| 归属于母公司股东的综合收益总额 | 40,429,048.51 | 30,906,134.94 | 173,909,931.33 | 99,541,525.95 |
| 归属于少数股东的综合收益总额 | 5,562,442.31 | 1,875,665.24 | 4,165,219 | 4,394,079.9 |
| 公告日期 | 2025-08-29 | 2025-04-26 | 2025-03-28 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |